This segment focuses on developing and commercializing DNA-based cancer diagnostics and personalized medicine solutions. It encompasses a portfolio of proprietary tests, including comparative genomic hybridization microarrays, next-generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes. These tests target difficult-to-diagnose hematological and human papillomavirus-associated cancers, such as cervical, anal, head, and neck cancers. The segment's research and development activities are geared towards identifying and validating novel biomarkers, improving diagnostic accuracy, and developing new tests for early cancer detection and therapy selection. By providing clinicians with comprehensive genomic information, this segment aims to enable more informed treatment decisions and improve patient outcomes. Strategic partnerships with pharmaceutical companies and research institutions further enhance the segment's capabilities and market reach.

The Biopharma Services segment provides contract research services to biotechnology and pharmaceutical companies, focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. This includes preclinical studies, clinical trial support, and translational research services. The segment leverages advanced genomic technologies and methodologies to identify potential drug targets, assess drug efficacy, and predict patient response. Research and development activities are centered on developing innovative assays and models to accelerate drug development and improve clinical trial outcomes. By partnering with leading biopharmaceutical companies, this segment contributes to the development of new cancer therapies and personalized treatment strategies. The acquisition of the Biopharma Business by Interpace Diagnostics highlights the value and growth potential of this segment.